Data showing Regeneron Pharmaceuticals, Inc./Roche Holding AG’s REGEN-COV (casirivimab/imdevimab) has strong efficacy in preventing COVID-19 with one dose may give the antibody cocktail an advantage on the market for drugs to prevent COVID-19 despite concerns about its long-term market durability due to looming competition from oral therapies.
Regeneron announced new data on 8 November from a 1,683-participant Phase III trial it is running with the National Institute...






